MicroRNA Expression in Subretinal Fluid in Eyes Affected by Rhegmatogenous Retinal Detachment

Int J Mol Sci. 2023 Feb 3;24(3):3032. doi: 10.3390/ijms24033032.

Abstract

Proliferative vitreoretinopathy (PVR) is an abnormal intraocular scarring process that can complicate cases of rhegmatogenous retinal detachment (RRD). Although previous studies have examined the relevance of microRNAs (miRNAs) in ophthalmic diseases, only a few studies have evaluated the expression profiles of microRNAs in subretinal fluid. We hypothesized that the expression profiles of specific miRNAs may change in response to RRD, in the subretinal fluid that is directly in contact with photoreceptors and the retinal pigment epithelium (RPE). We looked for a potential correlation between the expression of specific miRNAs in eyes with RRD and known clinical risk factors of PVR. A total of 24 patients (59 ± 11 years) who underwent scleral buckling procedure were enrolled in this prospective study. Twenty-four undiluted subretinal fluid samples were collected, RNA was isolated and qRT-PCR was performed to analyze the expression of 12 miRNAs. We found the existence of a positive association between the expression of miR-21 (p = 0.017, r = 0.515) and miR-34 (p = 0.030, r = 0.624) and the duration of symptoms related to retinal detachment. Moreover, the expression of miR-146a tended to decrease in patients who developed PVR. Subretinal fluid constitutes an intriguing biological matrix to evaluate the role of miRNAs leading to the development of PVR.

Keywords: PVR; RRD; SRF; miRNAs; myopia; proliferative vitreoretinopathy.

MeSH terms

  • Aged
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Middle Aged
  • Prospective Studies
  • Retinal Detachment* / genetics
  • Retinal Detachment* / surgery
  • Retrospective Studies
  • Scleral Buckling / adverse effects
  • Scleral Buckling / methods
  • Subretinal Fluid / metabolism
  • Vitreoretinopathy, Proliferative* / genetics

Substances

  • MicroRNAs

Grants and funding

This research received no external funding.